HIGH-DOSE AMSA AND BONE-MARROW RESCUE IN PATIENTS WITH SOLID TUMORS

  • 1 January 1982
    • journal article
    • research article
    • Vol. 66  (2) , 385-386
Abstract
The feasibility of high-dose AMSA [4''-(9-acridinylamino)-methanesulfon-m-anisidide] followed by autologous bone marrow rescue was studied in 7 patients with solid tumors. They received a total of 12 courses of treatment. Total doses ranged from 600-1000 mg/m2 per course. Major toxic effects were myelosuppression, fever of unknown origin and stomatitis. One patient with malignant melanoma had stable disease lasting 2 mo.; the other 6 had progressive disease.